Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.

NCT NCT02714595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02714595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Lead sponsor
Shionogi
Phase
Phase 3
Overall status
Completed
Start date
September 7, 2016
Completion date
April 22, 2019
Enrollment
152 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

bloodstream infections (bsi), complicated urinary tract infection (cuti), healthcare-associated pneumonia (hcap), hospital acquired pneumonia (hap), sepsis, ventilator associated pneumonia (vap)